Literature DB >> 9535779

A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency.

T J de Koning1, L Dorland, O P van Diggelen, A M Boonman, G J de Jong, W L van Noort, J De Schryver, M Duran, I E van den Berg, G J Gerwig, R Berger, B T Poll-The.   

Abstract

Three siblings suffered from an unusual disorder of cyclic vomiting and congenital hepatic fibrosis. Serum transferrin isoelectric focusing showed increased asialo- and disialotransferrin isoforms as seen in the carbohydrate-deficient glycoprotein (CDG) syndrome type I. Phosphomannomutase, which is deficient in most patients with type I CDG syndrome, was found to be normal in all three patients. Structural analysis of serum transferrin revealed nonglycosylated, hypoglycosylated, and normoglycosylated transferrin molecules. These findings suggested a defect in the early glycosylation pathway. Phosphomannose isomerase was found to be deficient and the defect was present in leucocytes, fibroblasts, and liver tissue. Phosphomannose isomerase deficiency appears to be a novel glycosylation disorder, which is biochemically indistinguishable from CDG syndrome type I. However, the clinical presentation is entirely different. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535779     DOI: 10.1006/bbrc.1998.8385

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Retrospective diagnosis of carbohydrate-deficient glycoprotein syndrome type Ib.

Authors:  D M Neele; C M Kneepkens; N M Verhoeven; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1999-12       Impact factor: 4.982

Review 2.  New disorders in carbohydrate metabolism: congenital disorders of glycosylation and their impact on the endocrine system.

Authors:  Bradley S Miller; Hudson H Freeze
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

3.  Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder.

Authors:  L J M Spaapen; J A Bakker; S B van der Meer; H J Sijstermans; R A Steet; R A Wevers; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 4.  Long-standing mild hypertransaminasaemia caused by congenital disorder of glycosylation (CDG) type IIx.

Authors:  P L Calvo; S Pagliardini; M Baldi; A Pucci; L Sturiale; D Garozzo; T Vinciguerra; C Barbera; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

5.  Carbohydrate-deficient glycoprotein syndrome type V: deficiency of dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase.

Authors:  C Körner; R Knauer; U Holzbach; F Hanefeld; L Lehle; K von Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

6.  Ontogeny of D-mannose transport and metabolism in rat small intestine.

Authors:  Mecedes Cano; Anunciación A Ilundain
Journal:  J Membr Biol       Date:  2010-06-04       Impact factor: 1.843

7.  Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie)

Authors:  S Kim; V Westphal; G Srikrishna; D P Mehta; S Peterson; J Filiano; P S Karnes; M C Patterson; H H Freeze
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 8.  Carbohydrate-deficient glycoprotein syndromes.

Authors:  N Gordon
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

9.  Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation.

Authors:  V Westphal; S Murch; S Kim; G Srikrishna; B Winchester; R Day; H H Freeze
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

10.  Genotypes and phenotypes of patients in the UK with carbohydrate-deficient glycoprotein syndrome type 1.

Authors:  F Imtiaz; V Worthington; M Champion; C Beesley; J Charlwood; P Clayton; G Keir; N Mian; B Winchester
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.